Itrascope 200 Capsule contains Itraconazole 200 mg, a broad-spectrum triazole antifungal agent effective against a variety of fungal infections. It is primarily indicated for the treatment of systemic and superficial mycoses, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis. Itraconazole exerts its antifungal activity by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the synthesis of ergosterol, a key component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. Itrascope 200 Capsule is administered orally and is well-absorbed when taken with food, enhancing its bioavailability. The dosage and duration of therapy depend on the type and severity of the infection, as well as patient response. Common adverse effects may include gastrointestinal disturbances, headache, dizziness, and rash. Caution is advised in patients with hepatic impairment, and liver function tests should be monitored during prolonged therapy. Itrascope 200 may interact with several drugs metabolized by the cytochrome P450 system; therefore, thorough medication review is recommended prior to initiation. This medication should be used under medical supervision to ensure efficacy and safety.